替奈普酶与阿替普酶在缺血性卒中取栓前的比较
这项随机试验纳入202例颈内动脉、基底动脉或大脑中动脉闭塞且适合取栓的缺血性卒中患者,在症状发作4.5小时内分别给予替奈普酶(0.25 mg/kg,最大25 mg)或阿替普酶(0.9 mg/kg,最大90 mg)。主要终点为初始血管造影时受累缺血区再灌注大于50%或无可取出血栓,替奈普酶组22% vs 阿替普酶组10%(发生率差12个百分点,95%CI 2至21;发生率比2.2,95%CI 1.1至4.4)。替奈普酶组90天改良Rankin量表评分中位数2 vs 3(共同比值比1.7,95%CI 1.0至2.8)。两组症状性颅内出血均为1%。
要点
- 取栓前4.5小时内,替奈普酶组主要终点(再灌注>50%或无可取出血栓)22% vs 阿替普酶组10%,发生率比2.2(95%CI 1.1至4.4)。
- 替奈普酶组90天改良Rankin量表评分中位数2 vs 阿替普酶组3,共同比值比1.7(95%CI 1.0至2.8)。
- 替奈普酶剂量为0.25 mg/kg(最大25 mg),阿替普酶为0.9 mg/kg(最大90 mg),均在症状发作4.5小时内给药。
- 两组症状性颅内出血发生率均为1%。
- 研究针对颈内动脉、基底动脉或大脑中动脉闭塞且适合取栓的缺血性卒中患者。
适用人群与场景
- 颈内动脉、基底动脉或大脑中动脉闭塞的缺血性卒中患者,适合行血管内取栓,且在症状发作4.5小时内。
处置流程与药物剂量
- 在症状发作4.5小时内,替奈普酶按0.25 mg/kg体重给药,最大剂量25 mg。
- 在症状发作4.5小时内,阿替普酶按0.9 mg/kg体重给药,最大剂量90 mg。
研究设计与关键结果
- 随机对照试验,纳入202例患者,替奈普酶组101例,阿替普酶组101例。
- 主要终点(初始血管造影时再灌注>50%或无可取出血栓):替奈普酶组22% vs 阿替普酶组10%,发生率差12个百分点(95%CI 2至21),发生率比2.2(95%CI 1.1至4.4),非劣效性P=0.002,优效性P=0.03。
- 90天改良Rankin量表评分中位数:替奈普酶组2 vs 阿替普酶组3,共同比值比1.7(95%CI 1.0至2.8),P=0.04。
- 症状性颅内出血:替奈普酶组1%,阿替普酶组1%。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于颈内动脉、基底动脉或大脑中动脉闭塞且适合取栓的缺血性卒中患者,在症状发作4.5小时内,替奈普酶较阿替普酶可能提高再灌注率并改善90天功能结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer activity than alteplase, is given as a bolus and may increase the incidence of vascular reperfusion.
METHODS: We randomly assigned patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery and who were eligible to undergo thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or alteplase (at a dose of 0.9 mg per kilogram; maximum dose, 90 mg) within 4.5 hours after symptom onset. The primary outcome was reperfusion of greater than 50% of the involved ischemic territory or an absence of retrievable thrombus at the time of the initial angiographic assessment. Noninferiority of tenecteplase was tested, followed by superiority. Secondary outcomes included the modified Rankin scale score (on a scale from 0 [no neurologic deficit] to 6 [death]) at 90 days. Safety outcomes were death and symptomatic intracerebral hemorrhage.
RESULTS: Of 202 patients enrolled, 101 were assigned to receive tenecteplase and 101 to receive alteplase. The primary outcome occurred in 22% of the patients treated with tenecteplase versus 10% of those treated with alteplase (incidence difference, 12 percentage points; 95% confidence interval [CI], 2 to 21; incidence ratio, 2.2; 95% CI, 1.1 to 4.4; P=0.002 for noninferiority; P=0.03 for superiority). Tenecteplase resulted in a better 90-day functional outcome than alteplase (median modified Rankin scale score, 2 vs. 3; common odds ratio, 1.7; 95% CI, 1.0 to 2.8; P=0.04). Symptomatic intracerebral hemorrhage occurred in 1% of the patients in each group.
CONCLUSIONS: Tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. (Funded by the National Health and Medical Research Council of Australia and others; EXTEND-IA TNK ClinicalTrials.gov number, NCT02388061 .).
参考来源
- Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018. PMID: 29694815. doi:10.1056/NEJMoa1716405
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。